Back

Integrating Novel Treatments to Advance Schizophrenia Management

Integrating Novel Treatments to Advance Schizophrenia Management

Gus Alva, MD; and Hara Oyedeji, MSN, MSEd, PMHNP-BC, APRN discuss how schizophrenia encompasses 3 distinct symptom domains beyond merely hallucinations, the limitations of current dopamine-blocking treatments, and the promising emergence of xanomeline trospium chloride as a novel muscarinic agonist that offers hope for more comprehensive treatment of this complex neuropsychiatric condition affecting millions worldwide.

Integrating Novel Treatments to Advance Schizophrenia Management

Episodes

All
All
2 experts in this video

Panelists discuss how schizophrenia affects 3.5 million Americans through 3 distinct symptom domains––positive symptoms (hallucinations), negative symptoms (social isolation, reduced functioning), and cognitive symptoms ––rather than just the commonly perceived “hearing voices.”